February 25th 2025
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
February 22nd 2025
Jeffrey Weber on the Role of Oncology Nurses in Treating Patients With Checkpoint Inhibitors
September 8th 2016Jeffrey Weber, MD, PhD, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, discusses the role of the oncology nurse when treating patients who have cancer with checkpoint inhibitors.